Iovance Biotherapeutics (IOVA) EBITDA Margin (2019 - 2026)
Iovance Biotherapeutics' EBITDA Margin was -42.70% in Q2 2026, up 131.90 percentage points from -174.60% a year earlier and up 58.81 percentage points from the prior quarter.
Iovance Biotherapeutics (IOVA) EBITDA Margin (2019 - 2026) Analysis & Trends
On a trailing twelve-month basis, Iovance Biotherapeutics' EBITDA Margin was -81.36% through Jun 30, 2026, up 72.26 percentage points year-over-year; for FY2025, it was -139.44%, up 78.55 percentage points from FY2024.
- In earlier years, EBITDA Margin was -217.98% in FY2024 (+36715.74 pp) and -36933.73% in FY2023.
- The Q2 2026 figure marks the highest quarterly EBITDA Margin in data going back to Q2 2023.
- Compared with a year earlier, EBITDA Margin has increased for nine straight quarters, with an average year-over-year change of +7856.51 percentage points over the last eight quarters.
- Over the past five years, the year-over-year gain in EBITDA Margin ranged from 10.23 percentage points (Q3 2025) to 43937.51 percentage points (Q2 2024).
- Per Business Quant data, IOVA's EBITDA Margin in the three quarters before Q2 2026 was -101.50% (Q1 2026), -73.25% (Q4 2025) and -127.36% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Iovance Biotherapeutics | 3.74 Bn | 2.45 Bn | 73.44 Mn | -11.91% |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -11.91% |
| Jun 30, 2026 | -42.70% |
| Mar 31, 2026 | -101.50% |
| Dec 31, 2025 | -73.22% |
| Sep 30, 2025 | -127.36% |
| Jun 30, 2025 | -174.60% |
| Mar 31, 2025 | -229.41% |
| Dec 31, 2024 | -98.55% |
| Sep 30, 2024 | -137.59% |
| Jun 30, 2024 | -300.31% |
| Mar 31, 2024 | -15,397.06% |
| Dec 31, 2023 | -23,733.82% |
| Sep 30, 2023 | -23,765.67% |
| Jun 30, 2023 | -44,237.82% |
| Mar 31, 2023 | -3,099.71% |
| Dec 31, 2022 | -6,070.24% |
| Sep 30, 2022 | -12,599.10% |
| Jun 30, 2022 | -25,333.51% |
| Mar 31, 2022 | -84,826.42% |
| Dec 31, 2021 | -72,062.22% |
Iovance Biotherapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IOVA&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "IOVA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IOVA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();